IFI-B · Gluconapin Suppression Series

Specimen SS-F-BTR-287 // ZERO-BITTER · IFI-B

Gluconapin Supp · T1 Cell-Free-A

Brassica oleracea

Broccoli/Kale

Tier IGluconapin Suppression Series

Target Trait

38%

% reduction

3-Butenyl glucosinolate reduction

Technical Specifications

SKU

SS-F-BTR-287

Genomic Edits

3

GC Content

44.7%

Construct Length

2,450 bp

Promoter System

T7 / SP6 RNA polymerase

Expression System

Cell-free in vitro transcription/translation

Host Strain

In vitro wheat germ extract

Receptor Target

TAS2R38 (suppression)

IFI Score

38

Pathway Edits

  • MAM3 RNAi reduces chain elongation toward C4 aliphatic glucosinolates
  • CYP79F1 RNAi suppresses Met-to-gluconapin C4 side-chain conversion
  • GSL-OH modification blocks 2-hydroxy derivative accumulation from gluconapin
  • AOP2 engineering redirects residual gluconapin flux away from bitter 2-hydroxy products

Key Interventions

MAM3 chain-elongation silencingCYP79F1 RNAiGSL-OH engineering

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
38
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier I Brassica oleracea lines with reduced gluconapin and progoitrin co-load, targeting breeders and food processors seeking consistent low-bitter profiles across the full C4 glucosinolate family.

License

$299 · Tier I License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?